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Abstract
The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale 
cancer genome studies in tumors from 50 different cancer types and/or subtypes that are of clinical 
and societal importance across the globe. Systematic studies of over 25,000 cancer genomes at the 
genomic, epigenomic, and transcriptomic levels will reveal the repertoire of oncogenic mutations, 
uncover traces of the mutagenic influences, define clinically-relevant subtypes for prognosis and 
therapeutic management, and enable the development of new cancer therapies.
The genomes of all cancers accumulate somatic mutations1. These include nucleotide 
substitutions, small insertions and deletions, chromosomal rearrangements and copy number 
changes that can affect protein-coding or regulatory components of genes. In addition, 
cancer genomes usually acquire somatic epigenetic “marks” compared to non-neoplastic 
tissues from the same organ, notably changes in the methylation status of cytosines at CpG 
dinucleotides.
A subset of the somatic mutations in cancer cells confers oncogenic properties such as 
growth advantage, tissue invasion and metastasis, angiogenesis, and evasion of apoptosis2. 
These are termed “driver” mutations. The identification of driver mutations will provide 
insights into cancer biology and highlight novel drug targets and diagnostic tests. 
Knowledge of cancer mutations has already led to the development of specific therapies, 
such as trastuzumab for HER2/neu positive breast cancers3 and imatinib, which targets 
BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia4,5. The remaining 
somatic mutations in cancer genomes that do not contribute to cancer development are 
called “passengers”. These mutations provide insights into the DNA damage and repair 
processes that have been operative during cancer development, including exogenous 
environmental exposures6,7. In most cancer genomes, it is anticipated that passenger 
mutations, as well as germline variants not yet catalogued in polymorphism databases, will 
substantially outnumber drivers.
Large-scale analyses of genes in tumors have revealed that the mutation load in cancer is 
abundant and heterogeneous8-13. Preliminary surveys of cancer genomes have already 
demonstrated their relevance in identifying new cancer genes that constitute potential 
therapeutic targets for several types of cancer, including PIK3CA14, BRAF15, NF110, 
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KDR10, PIK3R19, and histone methyltransferases and demethylases16,17. These projects 
have also yielded correlations between cancer mutations and prognosis, such as IDH1 and 
IDH2 mutations in several types of gliomas13,18. Advances in massively parallel 
sequencing technology have enabled sequencing of entire cancer genomes 19-22.
Following the launch of comprehensive cancer genome projects in the United Kingdom 
(Cancer Genome Project)23 and the United States (The Cancer Genome Atlas)24, cancer 
genome scientists and funding agencies met in Toronto (Canada) in October 2007 to discuss 
the opportunity to launch an international consortium. Key reasons for its formation were: 
(1) the scope is huge; (2) independent cancer genome initiatives could lead to duplication of 
effort or incomplete studies; (3) lack of standardization across studies could diminish the 
opportunities to merge and compare datasets; (4) the spectrum of many cancers is known to 
vary across the world; (5) an international consortium will accelerate the dissemination of 
datasets and analytical methods into the user community.
Working groups were created to develop strategies and policies that would form the basis 
for participation in the ICGC. The goals of the Consortium (Box 1) were released in April 
2008 (http://www.icgc.org/files/ICGC_April_29_2008.pdf). Since then, working groups and 
initial member projects have further refined the policies and plans for international 
collaboration.
Bioethical Framework
ICGC members agreed to a core set of bioethical elements for consent as a precondition of 
membership (Box 2). The Ethics and Policy Committee has created patient consent 
templates for both prospective collection and retrospective use of samples and data for 
ICGC projects. Differences in project-specific requirements and national legal frameworks 
may require some local amendments, while still reflecting the core principles of ICGC.
The ICGC recognizes a delicate balance between protecting participants' personal data and 
sharing these data to accelerate cancer research. Data access policies have been drawn up 
that are respectful of the rights of the donors, while allowing ICGC data derived from 
samples to be shared ethically among a wide research community. Two levels of access have 
been implemented. For data that cannot be used to identify individuals, “Open access” 
datasets are publically available. These include data such as gender, age range, histology, 
normalized gene expression values, epigenetic datasets, somatic mutations, summaries of 
germline data, and study protocols. “Controlled access” datasets contain germline genomic 
data and detailed clinical information that are associated to a unique individual whose 
personal identifiers have been removed. To access controlled datasets researchers must seek 
authorizations by contacting the Data Access Compliance Office (DACO) (http://
www.icgc.org/daco). An independent International Data Access Committee (IDAC) 
oversees the work of the DACO and provides assistance with resolving issues that arise.
Pathology and Clinical Annotation
Large-scale genomic studies of human tumors rely on the availability of fresh frozen tumor 
tissue. To address the paucity of samples that meet ICGC standards, many projects have 
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initiated prospective collections of high quality source material. Accordingly, the ICGC 
recommended procedures to promote consistency of sample processing throughout the 
Consortium and ensure a series of quality features such as high tissue integrity and tumor 
cell content. Each project will need to include diverse data types such as environmental 
exposures, clinical history of participants, tumor histopathology, and clinical outcomes.
Tumors display considerable clinical and biological heterogeneity which has resulted in a 
variety of tumor classifications. Within the ICGC, special measures are taken to promote the 
consistency of diagnosis. These include the coordination of diagnostic criteria among groups 
investigating tumors that are related, and policies that all samples will be reviewed by at 
least two independent reference pathologists. Furthermore, images of the stained tumor 
sections (or blood smear or cytospins for hematological neoplasias), from which diagnoses 
were made, will be stored and made available to the community.
Although different tumor types may require specific procedures for tumor acquisition or 
compilation of clinical and environmental data, ICGC has set guidelines regarding the use of 
common definitions and data standards. This will allow ICGC data users to identify 
correlations between tumor-specific molecular changes with clinical and histopathological 
data including prognosis, prediction of therapy response and tumor classification schemes 
for diagnosis.
Study Design and Statistical Issues
To identify cancer-related genes, one needs to detect genes that are mutated at a higher 
frequency than the background mutation rate. Given that several driver genes have been 
found to be mutated at low frequencies, ICGC will identify somatic mutation observed in at 
least 3% of tumors of a given subtype. ICGC determined that 500 samples would be needed 
per tumor type (although for rare tumor types, a smaller sample size may be justified). In 
practice, the degree of heterogeneity of a given tumor type is difficult to know in advance, 
such that some particularly heterogeneous tumor types may require larger sample 
collections.
Cancer Genome Analyses
High-quality catalogues of somatic mutations from whole cancer genomes will ultimately be 
the ICGC standard. Shotgun sequencing employing second generation technologies can 
detect all classes of somatic mutation implicated in cancer. Moreover, if the level of 
coverage is sufficient, comprehensive high quality catalogues of somatic mutations from 
individual cancer genomes can be acquired with >90% sensitivity and >95% specificity. In 
order to achieve this, it will be necessary to sequence both the genome of the cancer and of a 
normal tissue from the same individual to distinguish germline variants. Although a few 
genomes of this standard have already been generated, the cost and the continuing 
technology development will mean that interim analyses of particularly informative sectors 
of the genome will be carried out, for example of all coding exons and microRNAs.
For each individual cancer genome, the catalogue of somatic mutations will be 
supplemented by genome-wide information on the state of methylation of CpG 
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dinucleotides. The optimal strategies and technologies to achieve this are not yet clear. 
Moreover, the genomes of individual cancers will be accompanied, where possible, by 
analyses of the transcriptome. Although conventional array-based approaches currently 
predominate, it is preferable that RNA sequencing becomes the standard as sequencing has a 
greater dynamic range25 and provides additional information including novel transcripts and 
sequence variants26.
ICGC Datasets
The distributed nature of the Consortium coupled with the large size of the datasets makes it 
cumbersome to store all data in a single centralized repository. For this reason, the ICGC has 
adopted a “franchise” database model for integrating the information and making it available 
to the public. Under this model, each member project releases tumor information by copying 
it into its local franchise database after it has been quality checked. Each franchise database 
shares a common schema to describe the specimens, the associated clinical information, and 
their genome characterization data. ICGC primary data files, including sequencing traces, 
are sent to the National Center for Biotechnology Information (NCBI) and/or the European 
Bioinformatics Institute (EBI) for archiving, while interpreted data sets, such as somatic 
mutation calls, are stored in franchise databases. The ICGC franchise databases and web 
portal use BioMart27, a data federation technology originally developed for use in 
Ensembl28, and since adopted for use by multiple model organism and genome databases. 
The management of the ICGC data flow is the responsibility of the ICGC Data Coordination 
Center (DCC) located at the Ontario Institute for Cancer Research.
The DCC also operates the ICGC data portal which allows researchers to access both Open 
and Controlled access portions of the ICGC data. The portal provides a variety of user 
interfaces that range from simple gene-oriented queries (“Show me all the non-silent coding 
mutations identified in PIK3R1 for all cancers.”) to queries that integrate genomic, clinical, 
and functional information (“Show me all members of the toll receptor pathway having 
deletions in stage III breast cancer.”). These queries will be distributed across the franchise 
databases in a manner that is invisible to the user. The portal will also provide links to the 
primary files at NCBI and EBI, interfaces for generating tabular reports, data dumps in 
common bioinformatics formats, and other visualizations including genome browser tracks, 
pathway diagrams and survival curves. The portal is available via a link at http://
www.icgc.org.
At the time of this publication, the following cancer and reference datasets will be available 
through the ICGC web portal:
• Initial data releases from ICGC members for breast cancer (UK), liver cancer 
(Japan), and pancreatic cancer (Australia and Canada);
• A whole genome dataset of a metastatic melanoma cell line (COLO829)6;
• Open datasets from the TCGA for glioblastoma multiforme (GBM) and serous 
cystadenocarcinoma of the ovary (see below);
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• Whole exome somatic mutation data from 68 individuals with breast, colorectal, 
pancreatic cancer and GBM11-13;
• Links to the human reference genome (http://www.genomereference.org/) and gene 
annotations from the GENCODE Project (http://www.sanger.ac.uk/gencode/) 
which includes the CCDS gene set29;
• Links to dbSNP30 and the HapMap31 databases, providing access to common 
patterns of variation in reference population samples;
• Links to Reactome32, a curated database of biological pathways in human;
• A set of reference gene models, mirrored from ENSEMBL28.
The current version of the web portal provides an entry point to the open access data tier via 
interactive query as well as bulk download of data files. We expect that in mid 2010 both 
open access and controlled data will be available.
The ICGC recently established a bioinformatics analysis working group to compare 
pipelines, analytic methods, consistency within and among algorithms, and establish 
guidelines or best practices for the Consortium. Over time, significant resources will be 
deployed to develop strategies to analyze the large complex datasets generated by ICGC 
member projects, and provide value-added views of cancer genomic data by integrating 
them with other biological and epidemiological datasets.
Data Release and IP Policies
The data release policies of the ICGC are intended to maximize public benefit while, at the 
same time, protecting the interests and rights of sample donors and their relatives. Members 
of the ICGC are committed to the principles of rapid data release (with appropriate 
controlled access mechanisms), in concordance with the Toronto Statement33. ICGC 
members encourage the scientific community to use any data that targets specific genes and 
mutations, without any restrictions. In order to allow ICGC members the opportunity to be 
the first to publish global analyses from datasets they generate, the Consortium has also 
agreed that member projects may specify conditions that include a time limit during which 
other data users are asked to refrain from publishing global analyses (defined by several 
ICGC member projects as 100 tumors and matched controls), a provision referred to as a 
“publication moratorium”. In order to allow time for a dataset to be analyzed and submitted 
for publication, ICGC members will have at most one year after released datasets reach the 
specified threshold before third parties are permitted to submit manuscripts describing 
global analyses. Further details on data release guidelines for data producers, users and 
reviewers are available http://www.icgc.org. Users of ICGC data are expected to respect 
these terms and to cite this manuscript and the source of pre-publication data, including the 
version of the dataset. In cases of uncertainty, scientists using ICGC data are encouraged to 
contact the member projects to discuss publication plans.
ICGC members believe that maximum public benefit will be achieved if the data remain 
publicly accessible without patent restrictions hence no claims to possible intellectual 
property (IP) derived from primary data (including somatic mutations) will be made. Users 
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of ICGC data (including ICGC members) may elect to perform further research and to 
exercise their IP rights on these downstream discoveries. If this occurs, users are expected to 
implement licensing policies that do not obstruct further research.
Initial ICGC Projects
Currently nine countries and two European consortia have initiated cancer genome projects 
under the umbrella of the ICGC. The initial projects, listed in an online table that 
accompanies this article, will analyze tumor types found around the globe and throughout 
the human body affecting a diversity of organs including blood, brain, breast, kidney, liver, 
pancreas, stomach, oral cavity, and ovary. Over time, the ICGC will investigate fifty or more 
types and subtypes of cancer in adults and children. In the case of tumors with multiple 
subtypes, analyses should be focused on subtypes that may be defined on pathological, 
molecular, etiological or geographical differences. It is expected that some cancer types will 
be studied in parallel in different parts of the world, as the mutation profiles may differ 
among populations. The consortium has enabled the coordination of initial projects 
analyzing similar cancers in different countries, and in some cases, the redirection of 
resources to launch new projects.
The Cancer Genome Atlas (TCGA)
TCGA is a comprehensive program in cancer genomics that is jointly supported and 
managed by the National Cancer Institute and the National Human Genome Research 
Institute of the U.S. National Institutes of Health. TCGA began in 2006 as a pilot focused on 
three projects, glioblastoma multiforme (GBM), serous cystadenocarcinoma of the ovary, 
and lung squamous carcinoma, and has recently expanded to produce comprehensive 
genomic data sets for at least 10 additional cancers in the next two years. Given TCGA's 
contributions in launching the ICGC and cooperation to ensure that its policies (posted at 
http://cancergenome.nih.gov) are coordinated with those of the ICGC, TCGA's participation 
in the ICGC is considered to be equivalent to that of a full member. TCGA, however, is not 
able to join the ICGC formally at this time, because of technical and legal issues in the U.S. 
related to the mechanisms of the distribution of controlled-access data, although such data 
are directly available to investigators at http://cancergenome.nih.gov/dataportal. The 
National Institutes of Health policies relating to distribution of controlled-access datasets are 
being reviewed with the intent of enabling researchers to integrate and analyze across 
databases, for example, using the franchise model adopted by the ICGC. Meanwhile, TCGA 
is ensuring that projects are coordinated and data sets are compatible with those of the 
Consortium.
ICGC in the Next Decade
A large proportion of common cancers affecting patients around the world have been or will 
soon be selected for comprehensive cancer genome studies. Further efforts will be needed to 
leverage support and expertise to tackle the remaining tumor types, including rare cancers. 
The challenges of the ICGC are daunting due to the scope of the initiative, the complexity 
that is inherent to the heterogeneity of cancer and the limitations of current technologies to 
provide accurate long-range assemblies of highly rearranged chromosomes found in tumor 
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cells. These challenges underscore the importance of continued international coordination 
and further engagement of the scientific community in the next decade.
Moving Towards Clinical Applications
ICGC catalogues, which are expected to grow exponentially, will have immediate relevance 
in the cancer research community. Early insight into the biology of somatic mutations will 
come from functional studies in cell-based and animal models of tumors. Mutation screens 
in retrospective tumor banks linked to registries or clinical trials having significant clinical 
data will inform on the potential clinical utility of somatic mutations as biomarkers for 
prognosis or drug-response. Germline variants identified by ICGC projects may allow the 
discovery of genes predisposing to familial malignancies, such as PALB2 and pancreatic 
cancer12,34. High throughput screens of RNAi or small molecule libraries, and the 
adaptation of existing model systems, will play a major role in refining potential therapeutic 
candidates for further study35.
Translating these discoveries into clinical practice will require more sophisticated clinical 
trials that take into account the increases in phenotypic subdivisions, additional coordination 
to identify subjects having tumors with similar profiles, and increased use of biomarkers, 
genomic analyses, informatics and other technologies in the clinical development of new 
therapeutics. Given the tremendous potential for relatively low-cost genomic sequencing to 
reveal clinically useful information, we anticipate that in the not so distant future, partial or 
full cancer genomes will routinely be sequenced as part of the clinical evaluation of cancer 
patients and as part of their on-going clinical management. The successful and appropriate 
translation of cancer genome research into clinical practice will raise important social and 
ethical questions. It will be essential to combine the expertise of oncologists, biostatisticians, 
pathologists, geneticists, policy-makers and members of the biopharmaceutical industry to 
meet this challenge by developing new policies and clinical paradigms that enable rapid 
translation of many new biomarkers and cancer targets into new clinical tests and 
therapeutic interventions that will benefit cancer patients.
Box 1
Goals of the ICGC
• Coordinate the generation of comprehensive catalogues of genomic 
abnormalities (somatic mutations) in tumors in 50 different cancer types and/or 
subtypes which are of clinical and societal importance across the globe.
• Ensure high quality by defining the catalogue for each tumor type or subtype to 
include the full range of somatic mutations such as single-nucleotide variants, 
insertions, deletions, copy number changes, translocations and other 
chromosomal rearrangements, and to have the following features:
– Comprehensiveness, such that most cancer genes with somatic 
abnormalities occurring at a frequency of greater than 3% are discovered;
– High resolution, ideally at a single nucleotide level;
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– High quality, using common standards for pathology and technology;
– Data from matched non-tumor tissue, to distinguish somatic from 
inherited sequence variants and aberrations;
– Generate complementary catalogues of transcriptomic and epigenomic 
datasets from the same tumors.
• Make the data available to the entire research community as rapidly as possible, 
and with minimal restrictions, to accelerate research into the causes and control 
of cancer.
• Coordinate research efforts so that the interests and priorities of individual 
participants, self-organizing consortia, funding agencies and nations are 
addressed, including use of the burden of disease and the minimization of 
unnecessary redundancy in tumor analysis efforts.
• Support the dissemination of knowledge and standards related to new 
technologies, software, and methods to facilitate data integration and sharing 
with cancer researchers around the globe.
Box 2
Core Bioethical Elements
For prospective research, ICGC members should convey to potential participants, that:
• The ICGC is a coordinated effort among related scientific research projects 
being carried on around the world
• Participation in the ICGC and its component projects is voluntary
• Samples and data collected will be used for cancer research, which may include 
whole genome sequencing
• The patient's care will not be affected by their decision regarding participation
• The samples collected will be in limited quantities; access to them will be 
tightly controlled and will depend on the policy and practices of the ICGC-
member project. At least a small percentage of the samples may be shared with 
laboratories in other countries for the purposes of performing quality control 
studies
• Data derived from the samples collected and data generated by the ICGC 
members will be made accessible to ICGC members and other international 
researchers through either an open or a controlled access database under terms 
and conditions that will maximize participant confidentiality
• The researchers accessing data and samples will be required to affirm that they 
will not attempt to re-identify participants
• There is a remote risk of being identified from data available on the databases
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• Once data are placed in open databases, those data cannot be withdrawn later
• In controlled access databases the links to (local) data that can identify an 
individual will be destroyed upon withdrawal. Data previously distributed will 
continue to be used
• ICGC members agree not to make claims to possible IP on primary data
• No profit from eventual commercial products will be returned to subjects 
donating samples
For retrospective research, the above guidelines remain the same, with the exception that 
where the individual is no longer a patient, there will not be a concern that their care 
could be affected by participation.
For research involving samples and data from deceased individuals:
• Where required by law or ethics, consent should always be obtained from the 
families of a deceased individual if their samples and data are to be used; if re-
consent is not required, however, ethics review is sufficient
• Ethics committee review should be sought for all research proposing the use of 
existing sample and data collections
• Existing collections are a limited and valuable resource; access to them will be 
tightly controlled.
For research using anonymized samples, ethics review may be required in some 
jurisdictions.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank research participants who are generously donating samples and data, as well as physicians and clinical 
staff contributing to sample annotation and collection. A complete list of organizations that support ICGC projects 
accompanies this article online.
ICGC Marker Paper Author List As of 10 March 2010
International Cancer Genome Consortium (Project leaders and committee chairs are 
listed first and are designated with an asterix; other principal investigators and collaborators 
are listed in alphabetical order or as designated by the project leader).
Executive Committee
Page 9
Nature. Author manuscript; available in PMC 2010 October 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Thomas J. Hudson*1,2, Warwick Anderson3, Axel Aretz4, Anna D. Barker5, Cindy Bell6, 
Rosa R. Bernabé 7, M. K. Bhan8, Fabien Calvo9, Iiro Eerola10, Daniela S. Gerhard5, Alan 
Guttmacher11, Mark Guyer12, Fiona M. Hemsley13, Jennifer L. Jennings1, David Kerr14,15, 
Peter Klatt7, Patrik Kolar10, Jun Kusuda16, David P. Lane13, Frank Laplace17, Youyong 
Lu18, Gerd Nettekoven19, Brad Ozenberger12, Jane Peterson12, T.S. Rao8, Jacques 
Remacle10, Alan J. Schafer20, Tatsuhiro Shibata21, Michael R. Stratton22, Joseph G. 
Vockley5, Koichi Watanabe23, Huanming Yang24, Matthew M. F. Yuen25.
Ethics and Policy Committee
Bartha M. Knoppers*26, Martin Bobrow27, Anne Cambon-Thomsen28, Lynn G. Dressler29, 
Stephanie O. M. Dyke22, Yann Joly26, Kazuto Kato30, Karen L. Kennedy22, Pilar 
Nicolás31, Michael J. Parker32, Emmanuelle Rial-Sebbag28, Carlos M. Romeo-Casabona31, 
Kenna M. Shaw5, Susan Wallace26, Georgia L. Wiesner33,34, Nikolajs Zeps35,36.
Tissue and Clinical Annotation Working Group
1Ontario Institute for Cancer Research, Toronto, ON M5G 0A3, Canada.
2Departments of Medical Biophysics and Molecular Genetics, University of Toronto, Toronto, ON M5S 1A1, Canada.
3National Health and Medical Research Council, Canberra, Australian Capital Territory 2601, Australia.
4Project Management Agency, German Aerospace Center (DLR), 53175 Bonn, Germany.
5National Cancer Institute, US National Institutes of Health, Bethesda, MD 20892, USA.
6Genome Canada, Ottawa, ON K2P 1P1, Canada.
7Secretariat of State for Research, Ministry of Science and Innovation, 28027 Madrid, Spain.
8Department of Biotechnology, Ministry of Science & Technology, Government of India, New Delhi, Delhi 110003, India.
9Institut National du Cancer, 92513 Boulogne-Billancourt, France.
10Genomics and Systems Biology Unit, Health Research Directorate, European Commission, B-1049 Brussels, Belgium.
11Eunice Kennedy Shriver National Institute of Child Health and Human Development, US National Institutes of Health, Bethesda, 
MD 20892, USA.
12National Human Genome Research Institute, US National Institutes of Health, Bethesda, MD 20892, USA.
13Cancer Research UK, London WC2A 3PX, UK.
14Sidra Medical and Research Center, Qatar Foundation, Doha, Qatar.
15Department of Clinical Pharmacology, University of Oxford, Oxford OX2 6HE, UK.
16National Institute of Biomedical Innovation, Ibaraki, Osaka 567-0085, Japan.
17Division of Molecular Life Sciences, Federal Ministry of Education and Research, 11055 Berlin, Germany.
18Beijing Cancer Institute and Hospital, Peking University School of Oncology, 100142 Beijing, China.
19German Cancer Aid, 53113 Bonn, Germany.
20Wellcome Trust, London NW1 2BE, UK.
21National Cancer Center Research Institute, Chuo-ku, Tokyo 104-0045, Japan.
22Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, UK.
23Yokohama Institute, RIKEN, Yokohama, Kanagawa 230-0045, Japan.
24BGI-Shenzhen, Shenzhen, 518083 Guangdong, China.
25The Hong Kong University of Science and Technology, Hong Kong, China.
26Centre of Genomics and Policy, McGill University and Génome Québec Innovation Centre, Montreal, QC H3A 1A4, Canada.
27Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge CB2 0XY, UK.
28U558, INSERM, 31073 Toulouse, France.
29University of North Carolina School of Pharmacy, Division of Pharmaceutical Outcomes and Policy, Institute for 
Pharmacogenomics and Individualized Therapy, Chapel Hill, NC 27599, USA.
30Institute for Research in Humanities, Graduate School of Biostudies, Institute for Integrated Cell-Material Sciences, Kyoto 
University, Kyoto, Kyoto 606-8501, Japan.
31Inter-University Chair in Law and the Human Genome, University of Deusto, Bilbao, 48007 Bizkaia, Spain.
32The Ethox Centre, University of Oxford, Oxford OX3 7LF, UK.
33Department of Genetics, Case Western Reserve University, Cleveland, OH 44106, USA.
34Center for Human Genetics, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
35St John of God Pathology, Subiaco, Western Australia 6008, Australia.
36Schools of Surgery and Pathology and Laboratory Medicine, The University of Western Australia, Nedlands, Western Australia 
6009, Australia.
Page 10
Nature. Author manuscript; available in PMC 2010 October 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Peter Lichter*37, Andrew V. Biankin38,39, Christian Chabannon9,40, Lynda Chin41,42, 
Bruno Clément43, Enrique de Alava44, Françoise Degos45, Martin L. Ferguson46, Peter 
Geary47, D. Neil Hayes48, Thomas J. Hudson1,2, Amber L. Johns38, Arek Kasprzyk1, 
Hidewaki Nakagawa49, Robert Penny50, Miguel A. Piris51, Rajiv Sarin52, Aldo 
Scarpa53,54, Tatsuhiro Shibata21, Marc van de Vijver55,56.
Technologies Working Group
Michael R. Stratton*22, Hiroyuki Aburatani57, Mónica Bayés58,59, David D.L. 
Bowtell60,61, Peter J. Campbell22,62, Xavier Estivill58,59, P. Andrew Futreal22, Daniela S. 
Gerhard5, Sean M. Grimmond63, Ivo Gut64, Martin Hirst65, Carlos López-Otín66, Partha 
Majumder67, Marco Marra65, John D. McPherson1,68, Hidewaki Nakagawa49, Zemin 
Ning22, Xose S. Puente66, Yijun Ruan69, Tatsuhiro Shibata21, Hendrik G. Stunnenberg70, 
Harold Swerdlow22, Victor E. Velculescu71, Richard K. Wilson72,73, Hong H. Xue74,75, 
Liu Yang76.
37German Cancer Research Center, 69120 Heidelberg, Germany.
38Garvan Institute of Medical Research, University of New South Wales, Darlinghurst, Sydney, New South Wales 2010, Australia.
39Department of Surgery, Bankstown Hospital, Bankstown, Sydney, New South Wales 2200, Australia.
40Institut Paoli-Calmettes, 13273 Marseille, France.
41Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
42Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA.
43U991, INSERM, 35043 Rennes, France.
44Department of Hematology, Centro de Investigación del Cáncer, Hospital Universitario, Universidad de Salamanca, 37007 
Salamanca, Spain.
45Hôpital Beaujon, 92110 Clichy, France.
46MLF Consulting, Arlington, MA 02474, USA.
47Canadian Tumour Repository Network, Winnipeg, MN R3M 0V5, Canada.
48Department of Internal Medicine, Division of Medical Oncology, Lineberger Comprehensive Cancer Center, University of North 
Carolina, Chapel Hill, NC 27599, USA.
49Center for Genomic Medicine, RIKEN, Yokohama, Kanagawa 230-0045, Japan.
50International Genomics Consortium, Phoenix, AZ 85004, USA.
51Molecular Pathology Programme, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain.
52Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, Maharashtra 
410210, India.
53Department of Pathology, University of Verona, 37134 Verona, Italy.
54Center for Applied Research on Cancer (ARC-NET), Verona University Hospital, 37134 Verona, Italy.
55Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands.
56Academic Medical Center, 1015 AZ Amsterdam, The Netherlands.
57Research Center for Advanced Science and Technology, University of Tokyo, Meguro-ku, Tokyo 153-8904, Japan.
58Center for Genomic Regulation, Pompeu Fabra University, 08003 Barcelona, Spain.
59Public Health and Epidemiology Network Biomedical Research Center (CIBERESP), Barcelona, 08003 Catalonia, Spain.
60Peter MacCallum Cancer Centre, Melbourne, Victoria 3002, Australia.
61Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3010, Australia.
62Department of Haematology, University of Cambridge, Cambridge CB2 2XY, UK.
63Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 
4067, Australia.
64CEA/DSV/IG-Centre National de Genotypage, 91057 Evry, France.
65Canada's Michael Smith Genome Sciences Centre, BC Cancer Agency, Vancouver, BC V5Z 1L3, Canada.
66Departamento de Bioquímica y Biología Molecular, Instituto Universitario de Oncología, Universidad de Oviedo, 33006 Oviedo, 
Spain.
67National Institute of Biomedical Genomics, Kalyani, West Bengal 741251, India.
68Department of Medical Biophysics, University of Toronto, Toronto, ON M5S 1A1, Canada.
69Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore 138672, Singapore.
70Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen, 6500 HB Nijmegen, The Netherlands.
71Ludwig Center for Cancer Genetics and Therapeutics, Johns Hopkins Kimmel Cancer Center, Baltimore, MD 21231, USA.
72The Genome Center, Washington University School of Medicine, St. Louis, MO 63108, USA.
73Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63108, USA.
74Applied Genomics Center, Fok Ying Tung Graduate School, HKUST, Hong Kong, China.
75Department of Biochemistry, The Hong Kong University of Science and Technology, Hong Kong, China.
76Cancer Institute, Zhejiang University, 310009 Hangzhou, China.
Page 11
Nature. Author manuscript; available in PMC 2010 October 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Bioinformatics Analyses Working Group
Paul T. Spellman*77, Gary D. Bader78,79, Paul C. Boutros1, Peter J. Campbell22,62, Paul 
Flicek80, Gad Getz81, Roderic Guigó82, Guangwu Guo24, David Haussler83, Simon 
Heath64, Tim J. Hubbard22, Tao Jiang24, Steven M. Jones65, Qibin Li24, Nuria López-
Bigas84, Ruibang Luo24, Lakshmi Muthuswamy1, B. F. Francis Ouellette1, John V. 
Pearson63, Xose S. Puente66, Victor Quesada66, Benjamin J. Raphael85, Chris Sander86, 
Tatsuhiro Shibata21, Terence P. Speed87,88, Lincoln D. Stein1, Joshua M. Stuart89, Jon W. 
Teague22, Yasushi Totoki21, Tatsuhiko Tsunoda49, Alfonso Valencia90, David A. 
Wheeler91, Honglong Wu24, Shancen Zhao24, Guangyu Zhou24.
Data Coordination and Management Working Group
Lincoln D. Stein*1, Roderic Guigó82, Tim J. Hubbard22, Yann Joly26, Steven M. Jones65, 
Arek Kasprzyk1, Mark Lathrop64,92, Nuria López-Bigas84, B. F. Francis Ouellette1, Paul T. 
Spellman77, Jon W. Teague22, Gilles Thomas93,94, Alfonso Valencia90, Teruhiko 
Yoshida21.
Data Release, Data Tiers and Publications Working Group
Karen L. Kennedy*22, Myles Axton95, Stephanie O. M. Dyke22, P. Andrew Futreal22, 
Daniela S. Gerhard5, Chris Gunter96, Mark Guyer12, Thomas J. Hudson1,2, John D. 
McPherson1,68, Linda J. Miller97, Brad Ozenberger12, Kenna M. Shaw5.
Data Coordination Centre
77Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94510, USA.
78Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S 3E1, Canada.
79Banting and Best Department of Medical Research, University of Toronto, Toronto, ON M5S 3E1, Canada.
80European Molecular Biology Laboratory-European Bioinformatics Institute, Hinxton, Cambridge CB10 1SD, UK.
81Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
82Spanish National Bioinformatics Institute (INB) and Center for Genomic Regulation, Universitat Pompeu Fabra, 08003 Barcelona, 
Spain.
83Howard Hughes Medical Institute and Center for Biomolecular Science and Engineering, University of California Santa Cruz, Santa 
Cruz, CA 95064, USA.
84Research Unit on Biomedical Informatics, Department of Experimental and Health Science, Pompeu Fabra University, 08003 
Barcelona, Spain.
85Department of Computer Science & Center for Computational Molecular Biology, Brown University, Providence, RI 02912, USA.
86Computational Biology Center, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
87Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia.
88Department of Statistics, University of California Berkeley, Berkeley, CA 94720, USA.
89Department of Biomolecular Engineering, University of California Santa Cruz, Santa Cruz, CA 95064, USA.
90Spanish National Bioinformatics Institute (INB) and Structural Biology and Biocomputing Programme, Spanish National Cancer 
Research Centre (CNIO), 28029 Madrid, Spain.
91Human Genome Sequencing Center & Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 
77030, USA.
92Fondation Jean Dausset, Centre d'Etude du Polymorphisme Humain, 75010 Paris, France.
93Université Claude Bernard Lyon 1, 69622 Villeurbanne, France.
94Fondation Synergie Lyon Cancer, 69008 Lyon, France.
95Nature Genetics, New York, NY 10013-1917, USA.
96HudsonAlpha Institute for Biotechnology, Huntsville, AL 35806, USA.
97Nature and the Nature research journals, New York, NY 10013, USA.
Page 12
Nature. Author manuscript; available in PMC 2010 October 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Arek Kasprzyk*1, Lincoln D. Stein*1, Junjun Zhang1, Syed A. Haider98, Jianxin Wang1, 
Christina K. Yung1, Anthony Cross1, Yong Liang1, Saravanamuttu Gnaneshan1, Jonathan 
Guberman1, Jack Hsu1.
International Data Access Committee
Martin Bobrow*27, Don R. C. Chalmers99, Karl W. Hasel6, Yann Joly26, Terry S. H. 
Kaan100, Karen L. Kennedy22, Bartha M. Knoppers26, William W. Lowrance101, Tohru 
Masui16, Pilar Nicolás31, Emmanuelle Rial-Sebbag28, Laura Lyman Rodriguez12, 
Catherine Vergely102, Teruhiko Yoshida21.
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European Union/France – Renal Cancer (Renal cell carcinoma; focus on but not 
limited to clear cell subtype)
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Lathrop64,92, Didier Samuel146,147, Gilles Thomas93,94, Jessica Zucman-Rossi148.
Germany – Pediatric Brain Tumors (Medulloblastoma, Pediatric Pilocytic 
Astrocytoma)
Peter Lichter*37, Roland Eils*37,149, Benedikt Brors37, Jan O. Korbel80,150, Andrey 
Korshunov151, Pablo Landgraf152, Hans Lehrach153, Stefan Pfister37,154, Bernhard 
Radlwimmer37, Guido Reifenberger155, Michael D. Taylor156,157, Christof von 
Kalle158,159.
India – Oral Cancer (Gingivobuccal)
Partha P. Majumder*67, Rajiv Sarin52, T. S. Rao8, M. K. Bhan8.
Italy – Rare Pancreatic Tumors (Enteropancreatic endocrine tumors and rare 
pancreatic exocrine tumors; intraductal papillary mucinous neoplasms, solid 
pseudopapillary tumors, mucinous cystic neoplasms and other rarer tumors)
Aldo Scarpa*53,54, Paolo Pederzoli160, Rita T. Lawlor54, Massimo Delledonne161, Alberto 
Bardelli162,163, Andrew V. Biankin38,39, Sean M. Grimmond63, Thomas Gress164, David 
Klimstra165, Giuseppe Zamboni53.
Japan – Liver Cancer (Hepatocellular carcinoma; virus associated)
Tatsuhiro Shibata*21, Yusuke Nakamura49,166, Hidewaki Nakagawa49, Jun Kusuda16, 
Tatsuhiko Tsunoda49, Satoru Miyano166, Hiroyuki Aburatani57, Kazuto Kato30, Akihiro 
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157Labatt Brain Tumor Research Center, Hospital for Sick Children, Toronto, ON M5G 1X8, Canada.
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159Division of Translational Oncology, German Cancer Research Center, 69120 Heidelberg, Germany.
160Department of Surgery, University Hospital Trust of Verona, 37134 Verona, Italy.
161Functional Genomics Center, Department of Biotechnology, University of Verona, 37134 Verona, Italy.
162Laboratory of Molecular Genetics, Institute for Cancer Research and Treatment, University of Torino, 10060 Torino, Italy.
163FIRC Institute of Molecular Oncology, 20139 Milan, Italy.
164Department of Gastroenterology, Endocrinology, Metabolism and Infectiology, University of Marburg, 35043 Marburg, Germany.
165Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
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Spain – Chronic Lymphocytic Leukemia (with mutated and unmutated IgVH)
Elias Campo*167, Carlos López-Otín66, Xavier Estivill58,59, Roderic Guigó82, Silvia de 
Sanjosé168, Miguel A. Piris51, Emili Montserrat167, Marcos González-Díaz44, Xose S. 
Puente66, Pedro Jares167, Alfonso Valencia90, Heinz Himmelbaue58, Victor Quesada66, 
Silvia Bea167.
United Kingdom – Breast Cancer (Triple Negative/lobular/other)
Michael R. Stratton22, P. Andrew Futreal22, Peter J. Campbell22,62, Anne Vincent-
Salomon140, Andrea L. Richardson135,136, Jorge S. Reis-Filho134, Marc van de 
Vijver55,56, Gilles Thomas93,94, Jocelyne D. Masson-Jacquemier40, Samuel Aparicio169, 
Ake Borg129, Anne-Lise Børresen-Dale130,131, Carlos Caldas132, John A. Foekens133, 
Hendrik G. Stunnenberg70, Laura van't Veer55, Douglas F. Easton170, Paul T. Spellman77, 
Sancha Martin22.
United States – The Cancer Genome Atlas
The Cancer Genome Atlas Research Network.
Initial Scientific Planning Committee
Thomas J. Hudson*1,2, Lynda Chin*41,42, Bartha M. Knoppers*26, Eric S. Lander*81, Peter 
Lichter*37, Lincoln D. Stein*1, Michael R. Stratton*22, Warwick Anderson3, Anna D. 
Barker5, Cindy Bell6, Martin Bobrow27, Wylie Burke171, Francis S. Collins172, Carolyn C. 
Compton5, Ronald A. DePinho41,115, Douglas F. Easton170, P. Andrew Futreal22, Daniela 
S. Gerhard5, Anthony R. Green173, Mark Guyer12, Stanley R. Hamilton174, Tim J. 
Hubbard22, Olli P. Kallioniemi175, Karen L. Kennedy22, Timothy J. Ley72,176, Edison T. 
Liu69, Youyong Lu18, Partha Majumder67, Marco Marra65, Brad Ozenberger12, Jane 
Peterson12, Alan J. Schafer20, Paul T. Spellman77, Hendrik G. Stunnenberg70, Brandon J. 
Wainwright177, Richard K. Wilson72,73, Huanming Yang24.
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